Relapsing multiple sclerosis
Not yet recruitingStudy on the Safety and Effects of YTB323, Tocilizumab, and Cyclophosphamide in Patients with Relapsing Multiple Sclerosis Who Have Active Disease Despite Treatment
Study on the Safety and Effects of YTB323, Tocilizumab, and Cyclophosphamide in Patients with Relapsing Multiple Sclerosis Who Have Active Disease Despite Treatment
- Disease:Relapsing multiple sclerosis
- Substances:CyclophosphamideTocilizumab+2
Spain- Participants:18–64 years
- Substances:Cyclophosphamide
- Sponsor:Novartis Pharma AG










